insurance dropping glp-1 Perspectives from employers on the costs and issues associated with covering agonists for weight loss Why we are changing coverage

10.1534/genetics.104.029264 Genetics 17 FrancisR.BartonM

Abstract Treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) may attenuate kidney disease progression and cardiovascular events but their real-world impact on healthcare utilization and mortality in this population are not well-defined

Very large portions of anything

If a visible change is your goal, your provider will point you to the treatment that delivers it

Originally studied for its profound cytoprotective and gut-healing effects, its potential applications have expanded dramatically in preclinical research

As an added bonus the medications also made it very easy to give up alcohol